Pfizer Q1 FY17 results (Apr–Jun 2016) and concall

Pfizer India faced a challenging Q1 FY17 characterized by regulatory headwinds regarding its core brand 'Corex' and significant pricing pressure from the new NLEM policy. While the transition to Ind-AS accounting provided a book-keeping boost to margins via lower amortization and tax rates, operational growth remained sluggish at 3%. Management is prioritizing revenue recovery through volume growth and new launches, including potential sterile injectables from the global Hospira transaction.